A two-year-old AI coding startup raised $150 million at unicorn-plus valuation, while chip rivals to Nvidia collectively attracted billions in venture capital despite unproven technology.
OpenAI launched GPT-Rosalind for drug discovery as CEO Sam Altman faces physical threats at home. The dual narrative exposes AI's expanding ambitions and growing public backlash.
Startups and incumbents race to control autonomous AI systems as enterprises deploy agents faster than they can monitor or secure them.
Intel's Core Series 3 brings 40 TOPS NPU performance to sub-$700 laptops, betting on-device AI will offset Apple's efficiency lead as software matures.
Ramp data shows Anthropic now commands 30.6% of AI-spending customers, up from 24.3% in March, trailing OpenAI's 35.2% by a narrowing margin.
OpenAI is lobbying for broader AI adoption in biomedical research, citing speed gains, even as no fully AI-discovered drug has cleared Phase 3 trials.
Johannesburg's draft policy prioritizes computing infrastructure and research centers, marking a strategic bid for influence as Western democracies struggle with enforcement gaps.
GPT-5.4-Cyber rollout follows compromise of Axios library that exposed macOS app signing certificates, as OpenAI races Anthropic in cybersecurity AI.
